NRXP
NRx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.49
+1.75%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-17.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Feb 17, 2026 | Casper Joseph Michael · officer: Chief Operating Officer | A-Award | 100,000 | $2.39 |
| Sep 10, 2025 | Javitt Jonathan C · director, 10 percent owner, officer: Chairman and Chief Scientist | A-Award | 125,000 | $1.73 |
| Sep 10, 2025 | McBride Dennis · director | A-Award | 25,000 | $1.73 |
| Sep 10, 2025 | Hurvitz Chaim · director | A-Award | 25,000 | $1.73 |
| Sep 10, 2025 | Flynn Patrick John · director | A-Award | 50,000 | $1.73 |
| Feb 11, 2025 | ABRAMS MICHAEL S · officer: Chief Financial Officer | A-Award | 50,000 | $2.94 |
| Dec 18, 2024 | Javitt Jonathan C · director, 10 percent owner, officer: Chairman and Chief Scientist | Purchase | 40,000 | $1.17 |
| Sep 11, 2023 | Gorovitz Aaron · director | Purchase | 35,000 | $0.32 |
| Sep 11, 2023 | Hurvitz Chaim · director | Purchase | 70,000 | $0.29 |
| Aug 24, 2023 | Javitt Jonathan C · director, 10 percent owner, officer: Chief Scientist | Purchase | 100,000 | $0.33 |
| Aug 23, 2023 | Javitt Jonathan C · director, 10 percent owner, officer: Chief Scientist | Purchase | 200,000 | $0.32 |
| Dec 19, 2022 | Willard Stephen H · director: CHIEF EXECUTIVE OFFICER | Purchase | 50,000 | $1.17 |
| Dec 19, 2022 | VAN VOORHEES SETH · director: CHIEF FINANCIAL OFFICER | Purchase | 30,000 | $1.10 |
| Dec 19, 2022 | VAN VOORHEES SETH · director: CHIEF FINANCIAL OFFICER | Purchase | 7,021 | $1.11 |
| Dec 19, 2022 | VAN VOORHEES SETH · director: CHIEF FINANCIAL OFFICER | Purchase | 600 | $1.10 |
| Dec 19, 2022 | VAN VOORHEES SETH · director: CHIEF FINANCIAL OFFICER | Purchase | 8,716 | $1.12 |
| Dec 9, 2022 | Javitt Jonathan C · director | Sale | 400,000 | $1.00 |
| Dec 1, 2022 | Javitt Daniel C. · director | Sale | 13,730 | $1.50 |
| Dec 1, 2022 | Javitt Daniel C. · director | Sale | 8,441 | $1.50 |
| Nov 29, 2022 | Flynn Patrick John · director | Purchase | 2,500 | $1.24 |
| Nov 29, 2022 | Flynn Patrick John · director | Purchase | 1,750 | $1.25 |
| Nov 28, 2022 | VAN VOORHEES SETH · director: CHIEF FINANCIAL OFFICER | Purchase | 7,021 | $1.11 |
| Nov 28, 2022 | VAN VOORHEES SETH · director: CHIEF FINANCIAL OFFICER | Purchase | 600 | $1.10 |
| Nov 28, 2022 | VAN VOORHEES SETH · director: CHIEF FINANCIAL OFFICER | Purchase | 8,716 | $1.12 |
| Nov 23, 2022 | Hurvitz Chaim · director | Purchase | 40,408 | $1.10 |
| Nov 23, 2022 | Hurvitz Chaim · director | Purchase | 171,780 | $1.08 |
| Nov 23, 2022 | Hurvitz Chaim · director | Purchase | 287,812 | $0.99 |
| Nov 22, 2022 | Gorovitz Aaron · director | A-Award | 162,660 | $0.00 |
| Nov 22, 2022 | Glied Sharon · director | A-Award | 162,660 | $0.00 |
| Nov 22, 2022 | Flynn Patrick John · director | A-Award | 162,660 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 11Increased 14Reduced 2Sold out 34
| Filer | Action | Shares | Filed |
|---|---|---|---|
| B GROUP, INC. | New Position | 3,000,000 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,160,184 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 930,943 | Sep 2, 2026 |
| ADVISORSHARES INVESTMENTS LLC | Increased | 420,467 | Apr 28, 2026 |
| COMMONWEALTH EQUITY SERVICES, LLC | Increased | 397,431 | Apr 27, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 310,112 | May 15, 2026 |
| JANE STREET GROUP, LLC | Increased | 180,652 | May 12, 2026 |
| VANGUARD FIDUCIARY TRUST CO | New Position | 169,580 | May 8, 2026 |
| BLEAKLEY FINANCIAL GROUP, LLC | Unchanged | 117,204 | May 4, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 102,200 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 98,995 | May 13, 2026 |
| STATE STREET CORP | Unchanged | 86,984 | May 15, 2026 |
| XTX TOPCO LTD | New Position | 78,733 | May 15, 2026 |
| NORTHERN TRUST CORP | Increased | 43,469 | May 14, 2026 |
| HEADLANDS TECHNOLOGIES LLC | New Position | 39,394 | May 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Feb 17, 2026